Lataa...
Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors
Tyrosine kinase inhibitors (TKIs) have emerged as a new frontier of cancer therapy. These agents include inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), BRAF, mitogen-activated protein kinase kinase (also referred to as MEK), bcr-abl, c-KIT, pl...
Tallennettuna:
| Julkaisussa: | Oncol Rep |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859912/ https://ncbi.nlm.nih.gov/pubmed/33650659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2020.7911 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|